[ad_1]
LONDON, UK / ACCESSWIRE / July 15, 2022 / Roquefort Therapeutics (LSE:ROQ), the Primary Market listed biotech firm centered on early-stage alternatives within the biotechnology sector, is happy to announce that buying and selling within the Firm’s Odd Shares of 1 pence every (“Odd Shares”) has commenced on the OTCQB Enterprise Market in the US. The Firm’s OTCQB shares have the ticker: ROQAF
There isn’t a related capital increase with this cross buying and selling and Roquefort Therapeutics’s Odd Shares will proceed to commerce on its major itemizing, the Primary Market of the London Inventory Alternate, underneath the ticker ROQ.
Cross buying and selling on the OTCQB market permits the Firm to entry one of many world’s largest funding markets to develop its attain right into a broader pool of traders. Roquefort Therapeutics shares will likely be out there to US traders throughout US working hours and priced in US {dollars} and thus has the potential to allow higher liquidity within the Firm’s shares on the London Inventory Alternate by easing cross-border buying and selling for potential US traders. Additional details about the OTCQB market may be discovered at:
www.otcmarkets.com/be taught/market-101
As a Overseas Personal Issuer, Roquefort Therapeutics’s onboarding to the OTC Markets relies on satisfaction of the necessities for OTCQB as relevant to worldwide reporting firms together with satisfaction of the standards for the exemption underneath the US Alternate Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption consists of the disclosure obligation to make sure that sure data made public or distributed underneath residence market laws is made publicly out there on the corporate’s web site or different digital data supply system in English. Thus, the Firm can have no extra reporting obligations and incur minimal ongoing prices, in comparison with conventional main exchanges.
As a verified market, the OTCQB gives clear buying and selling for firms which have met a minimal bid worth take a look at, are present of their monetary reporting and have undergone an annual verification and administration certification course of. The cross-trading facility is supplied by OTC Markets Group Inc., positioned in New York. OTC Markets operates the world’s largest digital interdealer citation system for US dealer sellers and gives a number of media channels to extend the visibility of OTC-listed firms. On-line brokers reminiscent of Ameritrade, Constancy Investments, Tradestation, Charles Schwab and E-trade all provide OTCQB trades. US traders can discover real-time quotes, market data and entry present firm information and developments for Roquefort Therapeutics at https://www.otcmarkets.com/inventory/ROQAF/overview.
Roquefort Therapeutics has appointed MCAP LLP as its OTCQB Sponsor.
Stephen West, Roquefort Therapeutics Government Chairman, commented:
“Becoming a member of the OTCQB market gives Roquefort Therapeutics entry to a major funding market, and with minimal ongoing prices related and no extra reporting necessities, is a optimistic step ahead for the Firm. Having cross buying and selling capabilities is vital for the event of Roquefort Therapeutics and we consider this itemizing will present the Firm entry to US traders, each institutional and retail, considerably growing our publicity and buying and selling liquidity. Our goal is to construct a number one biotech firm centered on oncology medication and we’re happy to offer US traders the chance to take part in our progress.”
-Ends-
Enquiries:
Roquefort Therapeutics plc |
|
Stephen West (Chairman) |
+44 (0)20 3290 9339 |
Buchanan (Public Relations) Optiva Securities Restricted (Dealer) |
+44 (0)20 7466 5000 |
Christian Dennis |
+44 (0)20 3411 1881 |
For additional data on Roquefort Therapeutics, please go to www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Primary Market listed biotech firm growing merchandise by the pre-clinical part previous to partnering or promoting to large pharma. The Firm is targeted on growing first in school Midkine inhibiting medication for the remedy of most cancers.
Via in depth analysis leading to validation by publication in over 1,000 scientific publications, Roquefort Therapeutics has recognized the potential to use the broad therapeutic potential of Midkine for plenty of medical indications of great unmet wants. Roquefort Therapeutics holds an unique licence to the most important international IP portfolio on Midkine. The Midkine blocking drug growth markets have vital international market potential (within the multi-billion {dollars}). Roquefort Therapeutics’s pre-clinical programme is at present underway with an preliminary concentrate on most cancers.
This data is supplied by RNS, the information service of the London Inventory Alternate. RNS is accredited by the Monetary Conduct Authority to behave as a Main Info Supplier in the UK. Phrases and circumstances referring to the use and distribution of this data might apply. For additional data, please contact rns@lseg.com or go to www.rns.com.
SOURCE: Roquefort Therapeutics PLC
View supply model on accesswire.com:
https://www.accesswire.com/708694/Roquefort-Therapeutics-PLC-Proclaims-Graduation-of-Buying and selling-on-US-OTCQB-Enterprise-Market
[ad_2]
Source link